nodes	percent_of_prediction	percent_of_DWPC	metapath
Silodosin—ABCB1—Methylprednisolone—multiple sclerosis	0.0945	0.124	CbGbCtD
Silodosin—CYP3A4—Fingolimod—multiple sclerosis	0.0879	0.115	CbGbCtD
Silodosin—ABCB1—Mitoxantrone—multiple sclerosis	0.0689	0.0901	CbGbCtD
Silodosin—ABCB1—Betamethasone—multiple sclerosis	0.0614	0.0803	CbGbCtD
Silodosin—ABCB1—Prednisolone—multiple sclerosis	0.0606	0.0793	CbGbCtD
Silodosin—ABCB1—Prednisone—multiple sclerosis	0.0573	0.0749	CbGbCtD
Silodosin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0566	0.074	CbGbCtD
Silodosin—CYP3A4—Triamcinolone—multiple sclerosis	0.0429	0.0561	CbGbCtD
Silodosin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0413	0.054	CbGbCtD
Silodosin—CYP3A4—Betamethasone—multiple sclerosis	0.0368	0.0481	CbGbCtD
Silodosin—CYP3A4—Prednisolone—multiple sclerosis	0.0363	0.0475	CbGbCtD
Silodosin—ABCB1—Dexamethasone—multiple sclerosis	0.0357	0.0467	CbGbCtD
Silodosin—CYP3A4—Prednisone—multiple sclerosis	0.0343	0.0449	CbGbCtD
Silodosin—ABCB1—Methotrexate—multiple sclerosis	0.0287	0.0376	CbGbCtD
Silodosin—CYP3A4—Dexamethasone—multiple sclerosis	0.0214	0.028	CbGbCtD
Silodosin—Liver function test abnormal—Fingolimod—multiple sclerosis	0.00362	0.0239	CcSEcCtD
Silodosin—Sinusitis—Fingolimod—multiple sclerosis	0.00284	0.0187	CcSEcCtD
Silodosin—Cardiac disorder—Fingolimod—multiple sclerosis	0.00252	0.0166	CcSEcCtD
Silodosin—Vascular purpura—Cladribine—multiple sclerosis	0.00249	0.0164	CcSEcCtD
Silodosin—Angiopathy—Fingolimod—multiple sclerosis	0.00246	0.0162	CcSEcCtD
Silodosin—Mediastinal disorder—Fingolimod—multiple sclerosis	0.00245	0.0161	CcSEcCtD
Silodosin—Mental disorder—Fingolimod—multiple sclerosis	0.00238	0.0157	CcSEcCtD
Silodosin—Purpura—Cladribine—multiple sclerosis	0.00231	0.0152	CcSEcCtD
Silodosin—Palpitations—Fingolimod—multiple sclerosis	0.00209	0.0138	CcSEcCtD
Silodosin—Hepatic function abnormal—Azathioprine—multiple sclerosis	0.00207	0.0136	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.002	0.0132	CcSEcCtD
Silodosin—Nervous system disorder—Fingolimod—multiple sclerosis	0.00189	0.0125	CcSEcCtD
Silodosin—Skin disorder—Fingolimod—multiple sclerosis	0.00187	0.0123	CcSEcCtD
Silodosin—Hypotension—Fingolimod—multiple sclerosis	0.0018	0.0119	CcSEcCtD
Silodosin—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00167	0.011	CcSEcCtD
Silodosin—Hepatobiliary disease—Cladribine—multiple sclerosis	0.00162	0.0107	CcSEcCtD
Silodosin—Cardiac disorder—Cladribine—multiple sclerosis	0.00143	0.00941	CcSEcCtD
Silodosin—Angiopathy—Cladribine—multiple sclerosis	0.0014	0.0092	CcSEcCtD
Silodosin—Immune system disorder—Cladribine—multiple sclerosis	0.00139	0.00916	CcSEcCtD
Silodosin—Mediastinal disorder—Cladribine—multiple sclerosis	0.00139	0.00914	CcSEcCtD
Silodosin—Asthenia—Fingolimod—multiple sclerosis	0.00138	0.00912	CcSEcCtD
Silodosin—Pruritus—Fingolimod—multiple sclerosis	0.00137	0.00899	CcSEcCtD
Silodosin—Mental disorder—Cladribine—multiple sclerosis	0.00135	0.00888	CcSEcCtD
Silodosin—Diarrhoea—Fingolimod—multiple sclerosis	0.00132	0.00869	CcSEcCtD
Silodosin—Hepatobiliary disease—Azathioprine—multiple sclerosis	0.00132	0.00868	CcSEcCtD
Silodosin—Dizziness—Fingolimod—multiple sclerosis	0.00128	0.0084	CcSEcCtD
Silodosin—Vascular purpura—Triamcinolone—multiple sclerosis	0.00123	0.00812	CcSEcCtD
Silodosin—Headache—Fingolimod—multiple sclerosis	0.00121	0.00796	CcSEcCtD
Silodosin—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.00116	0.00767	CcSEcCtD
Silodosin—Purpura—Triamcinolone—multiple sclerosis	0.00114	0.00754	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00113	0.00746	CcSEcCtD
Silodosin—Immune system disorder—Azathioprine—multiple sclerosis	0.00113	0.00745	CcSEcCtD
Silodosin—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00113	0.00743	CcSEcCtD
Silodosin—Jaundice—Mitoxantrone—multiple sclerosis	0.0011	0.00724	CcSEcCtD
Silodosin—Nervous system disorder—Cladribine—multiple sclerosis	0.00107	0.00706	CcSEcCtD
Silodosin—Tachycardia—Cladribine—multiple sclerosis	0.00107	0.00703	CcSEcCtD
Silodosin—Skin disorder—Cladribine—multiple sclerosis	0.00106	0.007	CcSEcCtD
Silodosin—Sinusitis—Mitoxantrone—multiple sclerosis	0.00106	0.00696	CcSEcCtD
Silodosin—Hypotension—Cladribine—multiple sclerosis	0.00102	0.00673	CcSEcCtD
Silodosin—Breast disorder—Methylprednisolone—multiple sclerosis	0.000995	0.00655	CcSEcCtD
Silodosin—Insomnia—Cladribine—multiple sclerosis	0.000989	0.00651	CcSEcCtD
Silodosin—Vascular purpura—Prednisone—multiple sclerosis	0.000975	0.00642	CcSEcCtD
Silodosin—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000944	0.00622	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000921	0.00607	CcSEcCtD
Silodosin—Purpura—Prednisone—multiple sclerosis	0.000905	0.00596	CcSEcCtD
Silodosin—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000894	0.00589	CcSEcCtD
Silodosin—Urticaria—Cladribine—multiple sclerosis	0.000869	0.00572	CcSEcCtD
Silodosin—Abdominal pain—Cladribine—multiple sclerosis	0.000865	0.00569	CcSEcCtD
Silodosin—Skin disorder—Azathioprine—multiple sclerosis	0.000864	0.00569	CcSEcCtD
Silodosin—Hypotension—Azathioprine—multiple sclerosis	0.000831	0.00547	CcSEcCtD
Silodosin—Asthenia—Cladribine—multiple sclerosis	0.000785	0.00517	CcSEcCtD
Silodosin—Pruritus—Cladribine—multiple sclerosis	0.000774	0.0051	CcSEcCtD
Silodosin—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000768	0.00506	CcSEcCtD
Silodosin—Diarrhoea—Cladribine—multiple sclerosis	0.000748	0.00493	CcSEcCtD
Silodosin—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000727	0.00479	CcSEcCtD
Silodosin—Dizziness—Cladribine—multiple sclerosis	0.000723	0.00476	CcSEcCtD
Silodosin—Shock—Mitoxantrone—multiple sclerosis	0.000707	0.00466	CcSEcCtD
Silodosin—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000707	0.00466	CcSEcCtD
Silodosin—Abdominal pain—Azathioprine—multiple sclerosis	0.000703	0.00463	CcSEcCtD
Silodosin—Tachycardia—Mitoxantrone—multiple sclerosis	0.000702	0.00462	CcSEcCtD
Silodosin—Skin disorder—Mitoxantrone—multiple sclerosis	0.000698	0.0046	CcSEcCtD
Silodosin—Erectile dysfunction—Prednisone—multiple sclerosis	0.000694	0.00457	CcSEcCtD
Silodosin—Angiopathy—Methylprednisolone—multiple sclerosis	0.000691	0.00455	CcSEcCtD
Silodosin—Rash—Cladribine—multiple sclerosis	0.00069	0.00454	CcSEcCtD
Silodosin—Dermatitis—Cladribine—multiple sclerosis	0.000689	0.00454	CcSEcCtD
Silodosin—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000688	0.00453	CcSEcCtD
Silodosin—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000686	0.00452	CcSEcCtD
Silodosin—Headache—Cladribine—multiple sclerosis	0.000685	0.00451	CcSEcCtD
Silodosin—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000673	0.00443	CcSEcCtD
Silodosin—Hypotension—Mitoxantrone—multiple sclerosis	0.000672	0.00442	CcSEcCtD
Silodosin—Mental disorder—Methylprednisolone—multiple sclerosis	0.000667	0.00439	CcSEcCtD
Silodosin—Breast disorder—Methotrexate—multiple sclerosis	0.000659	0.00434	CcSEcCtD
Silodosin—Nausea—Cladribine—multiple sclerosis	0.00065	0.00428	CcSEcCtD
Silodosin—Syncope—Prednisolone—multiple sclerosis	0.000648	0.00427	CcSEcCtD
Silodosin—Loss of consciousness—Prednisolone—multiple sclerosis	0.000635	0.00418	CcSEcCtD
Silodosin—Angiopathy—Betamethasone—multiple sclerosis	0.000628	0.00414	CcSEcCtD
Silodosin—Angiopathy—Dexamethasone—multiple sclerosis	0.000628	0.00414	CcSEcCtD
Silodosin—Diarrhoea—Azathioprine—multiple sclerosis	0.000608	0.00401	CcSEcCtD
Silodosin—Syncope—Triamcinolone—multiple sclerosis	0.000596	0.00392	CcSEcCtD
Silodosin—Syncope—Methylprednisolone—multiple sclerosis	0.000595	0.00392	CcSEcCtD
Silodosin—Dizziness—Azathioprine—multiple sclerosis	0.000588	0.00387	CcSEcCtD
Silodosin—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000588	0.00387	CcSEcCtD
Silodosin—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000584	0.00385	CcSEcCtD
Silodosin—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000583	0.00384	CcSEcCtD
Silodosin—Shock—Prednisolone—multiple sclerosis	0.00058	0.00382	CcSEcCtD
Silodosin—Erectile dysfunction—Methotrexate—multiple sclerosis	0.00058	0.00382	CcSEcCtD
Silodosin—Tachycardia—Prednisolone—multiple sclerosis	0.000576	0.00379	CcSEcCtD
Silodosin—Urticaria—Mitoxantrone—multiple sclerosis	0.000571	0.00376	CcSEcCtD
Silodosin—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000568	0.00374	CcSEcCtD
Silodosin—Rash—Azathioprine—multiple sclerosis	0.000561	0.00369	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000561	0.00369	CcSEcCtD
Silodosin—Dermatitis—Azathioprine—multiple sclerosis	0.00056	0.00369	CcSEcCtD
Silodosin—Headache—Azathioprine—multiple sclerosis	0.000557	0.00367	CcSEcCtD
Silodosin—Dry mouth—Triamcinolone—multiple sclerosis	0.000553	0.00364	CcSEcCtD
Silodosin—Angiopathy—Prednisone—multiple sclerosis	0.000547	0.0036	CcSEcCtD
Silodosin—Immune system disorder—Prednisone—multiple sclerosis	0.000545	0.00359	CcSEcCtD
Silodosin—Syncope—Betamethasone—multiple sclerosis	0.000541	0.00356	CcSEcCtD
Silodosin—Syncope—Dexamethasone—multiple sclerosis	0.000541	0.00356	CcSEcCtD
Silodosin—Shock—Triamcinolone—multiple sclerosis	0.000534	0.00351	CcSEcCtD
Silodosin—Insomnia—Prednisolone—multiple sclerosis	0.000533	0.00351	CcSEcCtD
Silodosin—Shock—Methylprednisolone—multiple sclerosis	0.000532	0.00351	CcSEcCtD
Silodosin—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000531	0.0035	CcSEcCtD
Silodosin—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000531	0.00349	CcSEcCtD
Silodosin—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00053	0.00349	CcSEcCtD
Silodosin—Loss of consciousness—Betamethasone—multiple sclerosis	0.00053	0.00349	CcSEcCtD
Silodosin—Tachycardia—Triamcinolone—multiple sclerosis	0.000529	0.00349	CcSEcCtD
Silodosin—Mental disorder—Prednisone—multiple sclerosis	0.000529	0.00348	CcSEcCtD
Silodosin—Nausea—Azathioprine—multiple sclerosis	0.000528	0.00348	CcSEcCtD
Silodosin—Tachycardia—Methylprednisolone—multiple sclerosis	0.000528	0.00348	CcSEcCtD
Silodosin—Skin disorder—Methylprednisolone—multiple sclerosis	0.000526	0.00346	CcSEcCtD
Silodosin—Asthenia—Mitoxantrone—multiple sclerosis	0.000516	0.0034	CcSEcCtD
Silodosin—Hypotension—Methylprednisolone—multiple sclerosis	0.000506	0.00333	CcSEcCtD
Silodosin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000492	0.00324	CcSEcCtD
Silodosin—Insomnia—Triamcinolone—multiple sclerosis	0.000491	0.00323	CcSEcCtD
Silodosin—Insomnia—Methylprednisolone—multiple sclerosis	0.000489	0.00322	CcSEcCtD
Silodosin—Shock—Betamethasone—multiple sclerosis	0.000484	0.00319	CcSEcCtD
Silodosin—Shock—Dexamethasone—multiple sclerosis	0.000484	0.00319	CcSEcCtD
Silodosin—Nervous system disorder—Betamethasone—multiple sclerosis	0.000483	0.00318	CcSEcCtD
Silodosin—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000483	0.00318	CcSEcCtD
Silodosin—Tachycardia—Betamethasone—multiple sclerosis	0.00048	0.00316	CcSEcCtD
Silodosin—Tachycardia—Dexamethasone—multiple sclerosis	0.00048	0.00316	CcSEcCtD
Silodosin—Syncope—Prednisone—multiple sclerosis	0.000471	0.0031	CcSEcCtD
Silodosin—Urticaria—Prednisolone—multiple sclerosis	0.000469	0.00309	CcSEcCtD
Silodosin—Cardiac disorder—Methotrexate—multiple sclerosis	0.000468	0.00308	CcSEcCtD
Silodosin—Loss of consciousness—Prednisone—multiple sclerosis	0.000462	0.00304	CcSEcCtD
Silodosin—Hypotension—Dexamethasone—multiple sclerosis	0.00046	0.00303	CcSEcCtD
Silodosin—Hypotension—Betamethasone—multiple sclerosis	0.00046	0.00303	CcSEcCtD
Silodosin—Angiopathy—Methotrexate—multiple sclerosis	0.000457	0.00301	CcSEcCtD
Silodosin—Immune system disorder—Methotrexate—multiple sclerosis	0.000455	0.003	CcSEcCtD
Silodosin—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000454	0.00299	CcSEcCtD
Silodosin—Rash—Mitoxantrone—multiple sclerosis	0.000453	0.00298	CcSEcCtD
Silodosin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000453	0.00298	CcSEcCtD
Silodosin—Headache—Mitoxantrone—multiple sclerosis	0.00045	0.00297	CcSEcCtD
Silodosin—Insomnia—Dexamethasone—multiple sclerosis	0.000445	0.00293	CcSEcCtD
Silodosin—Insomnia—Betamethasone—multiple sclerosis	0.000445	0.00293	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000444	0.00292	CcSEcCtD
Silodosin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000443	0.00291	CcSEcCtD
Silodosin—Mental disorder—Methotrexate—multiple sclerosis	0.000442	0.00291	CcSEcCtD
Silodosin—Urticaria—Triamcinolone—multiple sclerosis	0.000431	0.00284	CcSEcCtD
Silodosin—Urticaria—Methylprednisolone—multiple sclerosis	0.00043	0.00283	CcSEcCtD
Silodosin—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000428	0.00282	CcSEcCtD
Silodosin—Nausea—Mitoxantrone—multiple sclerosis	0.000427	0.00281	CcSEcCtD
Silodosin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000425	0.0028	CcSEcCtD
Silodosin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000425	0.0028	CcSEcCtD
Silodosin—Shock—Prednisone—multiple sclerosis	0.000422	0.00278	CcSEcCtD
Silodosin—Nervous system disorder—Prednisone—multiple sclerosis	0.00042	0.00277	CcSEcCtD
Silodosin—Tachycardia—Prednisone—multiple sclerosis	0.000418	0.00275	CcSEcCtD
Silodosin—Skin disorder—Prednisone—multiple sclerosis	0.000416	0.00274	CcSEcCtD
Silodosin—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000402	0.00265	CcSEcCtD
Silodosin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000402	0.00265	CcSEcCtD
Silodosin—Urticaria—Betamethasone—multiple sclerosis	0.000391	0.00257	CcSEcCtD
Silodosin—Urticaria—Dexamethasone—multiple sclerosis	0.000391	0.00257	CcSEcCtD
Silodosin—Dizziness—Prednisolone—multiple sclerosis	0.00039	0.00257	CcSEcCtD
Silodosin—Asthenia—Triamcinolone—multiple sclerosis	0.000389	0.00256	CcSEcCtD
Silodosin—Abdominal pain—Betamethasone—multiple sclerosis	0.000389	0.00256	CcSEcCtD
Silodosin—Abdominal pain—Dexamethasone—multiple sclerosis	0.000389	0.00256	CcSEcCtD
Silodosin—Asthenia—Methylprednisolone—multiple sclerosis	0.000388	0.00256	CcSEcCtD
Silodosin—Insomnia—Prednisone—multiple sclerosis	0.000388	0.00255	CcSEcCtD
Silodosin—Pruritus—Triamcinolone—multiple sclerosis	0.000384	0.00253	CcSEcCtD
Silodosin—Pruritus—Methylprednisolone—multiple sclerosis	0.000383	0.00252	CcSEcCtD
Silodosin—Rash—Prednisolone—multiple sclerosis	0.000372	0.00245	CcSEcCtD
Silodosin—Dermatitis—Prednisolone—multiple sclerosis	0.000372	0.00245	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000371	0.00244	CcSEcCtD
Silodosin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00037	0.00244	CcSEcCtD
Silodosin—Headache—Prednisolone—multiple sclerosis	0.000369	0.00243	CcSEcCtD
Silodosin—Dizziness—Triamcinolone—multiple sclerosis	0.000359	0.00236	CcSEcCtD
Silodosin—Dizziness—Methylprednisolone—multiple sclerosis	0.000358	0.00236	CcSEcCtD
Silodosin—Asthenia—Dexamethasone—multiple sclerosis	0.000353	0.00233	CcSEcCtD
Silodosin—Asthenia—Betamethasone—multiple sclerosis	0.000353	0.00233	CcSEcCtD
Silodosin—Nervous system disorder—Methotrexate—multiple sclerosis	0.000351	0.00231	CcSEcCtD
Silodosin—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00035	0.00231	CcSEcCtD
Silodosin—Nausea—Prednisolone—multiple sclerosis	0.00035	0.00231	CcSEcCtD
Silodosin—Pruritus—Dexamethasone—multiple sclerosis	0.000348	0.00229	CcSEcCtD
Silodosin—Pruritus—Betamethasone—multiple sclerosis	0.000348	0.00229	CcSEcCtD
Silodosin—Skin disorder—Methotrexate—multiple sclerosis	0.000348	0.00229	CcSEcCtD
Silodosin—Rash—Triamcinolone—multiple sclerosis	0.000342	0.00225	CcSEcCtD
Silodosin—Dermatitis—Triamcinolone—multiple sclerosis	0.000342	0.00225	CcSEcCtD
Silodosin—Rash—Methylprednisolone—multiple sclerosis	0.000341	0.00225	CcSEcCtD
Silodosin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000341	0.00224	CcSEcCtD
Silodosin—Urticaria—Prednisone—multiple sclerosis	0.00034	0.00224	CcSEcCtD
Silodosin—Headache—Triamcinolone—multiple sclerosis	0.00034	0.00224	CcSEcCtD
Silodosin—Headache—Methylprednisolone—multiple sclerosis	0.000339	0.00223	CcSEcCtD
Silodosin—Abdominal pain—Prednisone—multiple sclerosis	0.000339	0.00223	CcSEcCtD
Silodosin—Diarrhoea—Dexamethasone—multiple sclerosis	0.000337	0.00222	CcSEcCtD
Silodosin—Diarrhoea—Betamethasone—multiple sclerosis	0.000337	0.00222	CcSEcCtD
Silodosin—Hypotension—Methotrexate—multiple sclerosis	0.000335	0.0022	CcSEcCtD
Silodosin—Dizziness—Dexamethasone—multiple sclerosis	0.000325	0.00214	CcSEcCtD
Silodosin—Dizziness—Betamethasone—multiple sclerosis	0.000325	0.00214	CcSEcCtD
Silodosin—Insomnia—Methotrexate—multiple sclerosis	0.000324	0.00213	CcSEcCtD
Silodosin—Nausea—Triamcinolone—multiple sclerosis	0.000322	0.00212	CcSEcCtD
Silodosin—Nausea—Methylprednisolone—multiple sclerosis	0.000321	0.00212	CcSEcCtD
Silodosin—Rash—Betamethasone—multiple sclerosis	0.00031	0.00204	CcSEcCtD
Silodosin—Rash—Dexamethasone—multiple sclerosis	0.00031	0.00204	CcSEcCtD
Silodosin—Dermatitis—Betamethasone—multiple sclerosis	0.00031	0.00204	CcSEcCtD
Silodosin—Dermatitis—Dexamethasone—multiple sclerosis	0.00031	0.00204	CcSEcCtD
Silodosin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000309	0.00204	CcSEcCtD
Silodosin—Headache—Dexamethasone—multiple sclerosis	0.000308	0.00203	CcSEcCtD
Silodosin—Headache—Betamethasone—multiple sclerosis	0.000308	0.00203	CcSEcCtD
Silodosin—Asthenia—Prednisone—multiple sclerosis	0.000307	0.00202	CcSEcCtD
Silodosin—Pruritus—Prednisone—multiple sclerosis	0.000303	0.002	CcSEcCtD
Silodosin—Diarrhoea—Prednisone—multiple sclerosis	0.000293	0.00193	CcSEcCtD
Silodosin—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000293	0.00193	CcSEcCtD
Silodosin—Nausea—Dexamethasone—multiple sclerosis	0.000292	0.00193	CcSEcCtD
Silodosin—Nausea—Betamethasone—multiple sclerosis	0.000292	0.00193	CcSEcCtD
Silodosin—Urticaria—Methotrexate—multiple sclerosis	0.000285	0.00187	CcSEcCtD
Silodosin—Dizziness—Prednisone—multiple sclerosis	0.000283	0.00187	CcSEcCtD
Silodosin—Abdominal pain—Methotrexate—multiple sclerosis	0.000283	0.00186	CcSEcCtD
Silodosin—Rash—Prednisone—multiple sclerosis	0.00027	0.00178	CcSEcCtD
Silodosin—Dermatitis—Prednisone—multiple sclerosis	0.00027	0.00178	CcSEcCtD
Silodosin—Headache—Prednisone—multiple sclerosis	0.000268	0.00177	CcSEcCtD
Silodosin—Asthenia—Methotrexate—multiple sclerosis	0.000257	0.00169	CcSEcCtD
Silodosin—Nausea—Prednisone—multiple sclerosis	0.000255	0.00168	CcSEcCtD
Silodosin—Pruritus—Methotrexate—multiple sclerosis	0.000253	0.00167	CcSEcCtD
Silodosin—Diarrhoea—Methotrexate—multiple sclerosis	0.000245	0.00161	CcSEcCtD
Silodosin—Dizziness—Methotrexate—multiple sclerosis	0.000237	0.00156	CcSEcCtD
Silodosin—Rash—Methotrexate—multiple sclerosis	0.000226	0.00149	CcSEcCtD
Silodosin—Dermatitis—Methotrexate—multiple sclerosis	0.000226	0.00149	CcSEcCtD
Silodosin—Headache—Methotrexate—multiple sclerosis	0.000224	0.00148	CcSEcCtD
Silodosin—Nausea—Methotrexate—multiple sclerosis	0.000213	0.0014	CcSEcCtD
Silodosin—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	9.82e-05	0.00118	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—LINGO1—multiple sclerosis	9.82e-05	0.00118	CbGpPWpGaD
Silodosin—ABCB1—Allograft Rejection—IL2—multiple sclerosis	9.79e-05	0.00117	CbGpPWpGaD
Silodosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	9.73e-05	0.00117	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—CXCL10—multiple sclerosis	9.69e-05	0.00116	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	9.68e-05	0.00116	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CNR1—multiple sclerosis	9.56e-05	0.00115	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—RGS1—multiple sclerosis	9.51e-05	0.00114	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—POMC—multiple sclerosis	9.44e-05	0.00113	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.4e-05	0.00113	CbGpPWpGaD
Silodosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	9.29e-05	0.00111	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CXCL13—multiple sclerosis	9.28e-05	0.00111	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CCR1—multiple sclerosis	9.28e-05	0.00111	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	9.25e-05	0.00111	CbGpPWpGaD
Silodosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	9.09e-05	0.00109	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CCR1—multiple sclerosis	9.08e-05	0.00109	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CXCL13—multiple sclerosis	9.08e-05	0.00109	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—CCR5—multiple sclerosis	9.05e-05	0.00109	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—GPR65—multiple sclerosis	9.02e-05	0.00108	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—S1PR1—multiple sclerosis	8.96e-05	0.00108	CbGpPWpGaD
Silodosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	8.76e-05	0.00105	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—GPC5—multiple sclerosis	8.72e-05	0.00105	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—LINGO1—multiple sclerosis	8.72e-05	0.00105	CbGpPWpGaD
Silodosin—ABCB4—Metabolism—ALB—multiple sclerosis	8.61e-05	0.00103	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CXCL10—multiple sclerosis	8.6e-05	0.00103	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TAGAP—multiple sclerosis	8.51e-05	0.00102	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—PTGER4—multiple sclerosis	8.45e-05	0.00101	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—CCL5—multiple sclerosis	8.34e-05	0.001	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.29e-05	0.000994	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CCR1—multiple sclerosis	8.25e-05	0.000989	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CXCL13—multiple sclerosis	8.25e-05	0.000989	CbGpPWpGaD
Silodosin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.24e-05	0.000988	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	8.22e-05	0.000986	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CXCR3—multiple sclerosis	8.16e-05	0.000979	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CCL3—multiple sclerosis	7.97e-05	0.000956	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CCR2—multiple sclerosis	7.94e-05	0.000952	CbGpPWpGaD
Silodosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	7.71e-05	0.000925	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—PTGER4—multiple sclerosis	7.67e-05	0.00092	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—SRM—multiple sclerosis	7.67e-05	0.000919	CbGpPWpGaD
Silodosin—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	7.63e-05	0.000916	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—RGS1—multiple sclerosis	7.62e-05	0.000914	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TAGAP—multiple sclerosis	7.56e-05	0.000907	CbGpPWpGaD
Silodosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	7.54e-05	0.000905	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—CCR5—multiple sclerosis	7.51e-05	0.000901	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—S1PR1—multiple sclerosis	7.44e-05	0.000892	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.43e-05	0.000891	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CXCR3—multiple sclerosis	7.41e-05	0.000889	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CCL5—multiple sclerosis	7.41e-05	0.000888	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CNR1—multiple sclerosis	7.33e-05	0.000879	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—GPC5—multiple sclerosis	7.24e-05	0.000868	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—GPR65—multiple sclerosis	7.23e-05	0.000867	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CCR2—multiple sclerosis	7.21e-05	0.000865	CbGpPWpGaD
Silodosin—ABCB1—Allograft Rejection—TNF—multiple sclerosis	7.13e-05	0.000855	CbGpPWpGaD
Silodosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	7.09e-05	0.000851	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—POMC—multiple sclerosis	7.07e-05	0.000848	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—PTGER4—multiple sclerosis	7.01e-05	0.000841	CbGpPWpGaD
Silodosin—ADRA1D—GPCR ligand binding—CCL2—multiple sclerosis	6.92e-05	0.00083	CbGpPWpGaD
Silodosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	6.85e-05	0.000821	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CXCR3—multiple sclerosis	6.77e-05	0.000812	CbGpPWpGaD
Silodosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	6.7e-05	0.000804	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CCR5—multiple sclerosis	6.67e-05	0.0008	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CNR1—multiple sclerosis	6.65e-05	0.000798	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CCL3—multiple sclerosis	6.62e-05	0.000793	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCR1—multiple sclerosis	6.61e-05	0.000793	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CXCL13—multiple sclerosis	6.61e-05	0.000793	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—S1PR1—multiple sclerosis	6.61e-05	0.000793	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CXCL10—multiple sclerosis	6.6e-05	0.000791	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CCR2—multiple sclerosis	6.59e-05	0.00079	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.57e-05	0.000788	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—GPC5—multiple sclerosis	6.43e-05	0.000771	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PTGER4—multiple sclerosis	6.37e-05	0.000764	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—RGS1—multiple sclerosis	6.33e-05	0.000759	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—BCHE—multiple sclerosis	6.31e-05	0.000756	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—PTGER4—multiple sclerosis	6.23e-05	0.000747	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CXCR3—multiple sclerosis	6.15e-05	0.000738	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CNR1—multiple sclerosis	6.08e-05	0.000729	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CXCR3—multiple sclerosis	6.02e-05	0.000721	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—GPR65—multiple sclerosis	6e-05	0.000719	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CXCL10—multiple sclerosis	5.99e-05	0.000718	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CCR2—multiple sclerosis	5.98e-05	0.000718	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	5.89e-05	0.000706	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CCL3—multiple sclerosis	5.88e-05	0.000705	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—POMC—multiple sclerosis	5.87e-05	0.000704	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CCR2—multiple sclerosis	5.85e-05	0.000702	CbGpPWpGaD
Silodosin—ADRA1B—GPCR ligand binding—CCL2—multiple sclerosis	5.74e-05	0.000689	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CCL5—multiple sclerosis	5.68e-05	0.000681	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PTGER4—multiple sclerosis	5.66e-05	0.000678	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—RGS1—multiple sclerosis	5.62e-05	0.000674	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CNR1—multiple sclerosis	5.52e-05	0.000662	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCR1—multiple sclerosis	5.48e-05	0.000658	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CXCL13—multiple sclerosis	5.48e-05	0.000658	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CXCL10—multiple sclerosis	5.47e-05	0.000657	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CXCR3—multiple sclerosis	5.46e-05	0.000655	CbGpPWpGaD
Silodosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	5.45e-05	0.000654	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CNR1—multiple sclerosis	5.4e-05	0.000648	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP24A1—multiple sclerosis	5.4e-05	0.000648	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP27B1—multiple sclerosis	5.4e-05	0.000648	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—GPR65—multiple sclerosis	5.33e-05	0.000639	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CCR2—multiple sclerosis	5.31e-05	0.000637	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	5.23e-05	0.000627	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—POMC—multiple sclerosis	5.22e-05	0.000625	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CCL5—multiple sclerosis	5.16e-05	0.000618	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—CCR5—multiple sclerosis	5.12e-05	0.000613	CbGpPWpGaD
Silodosin—ADRA1A—GPCR ligand binding—CCL2—multiple sclerosis	5.1e-05	0.000612	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—IL2RA—multiple sclerosis	5.04e-05	0.000605	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CXCL10—multiple sclerosis	4.97e-05	0.000596	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GPC5—multiple sclerosis	4.94e-05	0.000592	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CNR1—multiple sclerosis	4.9e-05	0.000588	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCR1—multiple sclerosis	4.87e-05	0.000584	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CXCL13—multiple sclerosis	4.87e-05	0.000584	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CXCL10—multiple sclerosis	4.86e-05	0.000583	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SRM—multiple sclerosis	4.72e-05	0.000566	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CCL5—multiple sclerosis	4.71e-05	0.000565	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCL3—multiple sclerosis	4.71e-05	0.000565	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CCR5—multiple sclerosis	4.65e-05	0.000557	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—IL2RA—multiple sclerosis	4.58e-05	0.000549	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTGER4—multiple sclerosis	4.53e-05	0.000544	CbGpPWpGaD
Silodosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	4.52e-05	0.000543	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PGR—multiple sclerosis	4.46e-05	0.000535	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CXCL10—multiple sclerosis	4.42e-05	0.00053	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CXCR3—multiple sclerosis	4.38e-05	0.000525	CbGpPWpGaD
Silodosin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	4.38e-05	0.000525	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CD28—multiple sclerosis	4.34e-05	0.00052	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CCL5—multiple sclerosis	4.28e-05	0.000513	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCR2—multiple sclerosis	4.26e-05	0.000511	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—CCR5—multiple sclerosis	4.25e-05	0.000509	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CCL5—multiple sclerosis	4.19e-05	0.000502	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—IL2RA—multiple sclerosis	4.18e-05	0.000502	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—RRM1—multiple sclerosis	4.09e-05	0.000491	CbGpPWpGaD
Silodosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	4.02e-05	0.000482	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—POMC—multiple sclerosis	4e-05	0.000479	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CNR1—multiple sclerosis	3.93e-05	0.000471	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCL3—multiple sclerosis	3.91e-05	0.000469	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CCR5—multiple sclerosis	3.86e-05	0.000462	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CCL5—multiple sclerosis	3.8e-05	0.000456	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL2RA—multiple sclerosis	3.8e-05	0.000456	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—APOE—multiple sclerosis	3.79e-05	0.000455	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.78e-05	0.000453	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—CCR5—multiple sclerosis	3.77e-05	0.000452	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.77e-05	0.000452	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTGER4—multiple sclerosis	3.76e-05	0.000451	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—IL2RA—multiple sclerosis	3.72e-05	0.000446	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PGR—multiple sclerosis	3.7e-05	0.000444	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.69e-05	0.000443	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CXCR3—multiple sclerosis	3.63e-05	0.000436	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—POMC—multiple sclerosis	3.63e-05	0.000435	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CD28—multiple sclerosis	3.6e-05	0.000432	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—CCL2—multiple sclerosis	3.55e-05	0.000426	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CXCL10—multiple sclerosis	3.54e-05	0.000424	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCR2—multiple sclerosis	3.53e-05	0.000424	CbGpPWpGaD
Silodosin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.52e-05	0.000422	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCL3—multiple sclerosis	3.47e-05	0.000416	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CCR5—multiple sclerosis	3.42e-05	0.000411	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL2RA—multiple sclerosis	3.38e-05	0.000405	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTGER4—multiple sclerosis	3.34e-05	0.000401	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	3.33e-05	0.000399	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	3.33e-05	0.000399	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—POMC—multiple sclerosis	3.32e-05	0.000398	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PGR—multiple sclerosis	3.29e-05	0.000395	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CNR1—multiple sclerosis	3.26e-05	0.000391	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—POMC—multiple sclerosis	3.26e-05	0.000391	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CXCR3—multiple sclerosis	3.23e-05	0.000387	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—TYK2—multiple sclerosis	3.23e-05	0.000387	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CD28—multiple sclerosis	3.2e-05	0.000383	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCR2—multiple sclerosis	3.14e-05	0.000377	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CD86—multiple sclerosis	3.09e-05	0.000371	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCL5—multiple sclerosis	3.05e-05	0.000365	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GPC5—multiple sclerosis	3.04e-05	0.000365	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—POMC—multiple sclerosis	3.01e-05	0.000361	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—ALB—multiple sclerosis	2.97e-05	0.000356	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—IL2—multiple sclerosis	2.96e-05	0.000354	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—CCL2—multiple sclerosis	2.95e-05	0.000354	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	2.95e-05	0.000353	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CXCL10—multiple sclerosis	2.94e-05	0.000352	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	2.9e-05	0.000347	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—SPP1—multiple sclerosis	2.82e-05	0.000338	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCR5—multiple sclerosis	2.74e-05	0.000329	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL2RA—multiple sclerosis	2.7e-05	0.000324	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—IL2—multiple sclerosis	2.68e-05	0.000322	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—TYK2—multiple sclerosis	2.68e-05	0.000321	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	2.68e-05	0.000321	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	2.62e-05	0.000314	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	2.61e-05	0.000313	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CD86—multiple sclerosis	2.57e-05	0.000308	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCL5—multiple sclerosis	2.53e-05	0.000303	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.52e-05	0.000302	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—APOE—multiple sclerosis	2.5e-05	0.000299	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—IL2—multiple sclerosis	2.45e-05	0.000294	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	2.38e-05	0.000285	CbGpPWpGaD
Silodosin—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.36e-05	0.000284	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—BCHE—multiple sclerosis	2.35e-05	0.000282	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—SPP1—multiple sclerosis	2.34e-05	0.000281	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	2.28e-05	0.000274	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCR5—multiple sclerosis	2.28e-05	0.000273	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CD80—multiple sclerosis	2.26e-05	0.000271	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	2.25e-05	0.000269	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL2RA—multiple sclerosis	2.24e-05	0.000269	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL2—multiple sclerosis	2.23e-05	0.000267	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	2.18e-05	0.000261	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—POMC—multiple sclerosis	2.14e-05	0.000257	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCL2—multiple sclerosis	2.1e-05	0.000252	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	2.08e-05	0.000249	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—APOE—multiple sclerosis	2.07e-05	0.000249	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—MAPK1—multiple sclerosis	2.05e-05	0.000246	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	2.02e-05	0.000243	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	1.99e-05	0.000239	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	1.98e-05	0.000237	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TYK2—multiple sclerosis	1.91e-05	0.000229	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CD80—multiple sclerosis	1.87e-05	0.000225	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	1.84e-05	0.000221	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	1.78e-05	0.000213	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	1.74e-05	0.000209	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.7e-05	0.000204	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	1.66e-05	0.0002	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL2—multiple sclerosis	1.59e-05	0.00019	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	1.58e-05	0.00019	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	1.58e-05	0.00019	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—IL6—multiple sclerosis	1.58e-05	0.000189	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	1.55e-05	0.000186	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.51e-05	0.000182	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MMP9—multiple sclerosis	1.5e-05	0.00018	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.45e-05	0.000174	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—APOE—multiple sclerosis	1.41e-05	0.00017	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	1.4e-05	0.000168	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—STAT3—multiple sclerosis	1.33e-05	0.00016	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	1.32e-05	0.000158	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	1.31e-05	0.000157	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	1.25e-05	0.000149	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MYC—multiple sclerosis	1.24e-05	0.000149	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TGFB1—multiple sclerosis	1.24e-05	0.000148	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—POMC—multiple sclerosis	1.21e-05	0.000146	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAPK1—multiple sclerosis	1.21e-05	0.000145	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	1.17e-05	0.00014	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	1.16e-05	0.000139	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ALB—multiple sclerosis	1.11e-05	0.000133	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	1.11e-05	0.000133	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	1.11e-05	0.000133	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	1.03e-05	0.000123	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	1.03e-05	0.000123	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	1.01e-05	0.000121	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	9.84e-06	0.000118	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL6—multiple sclerosis	9.32e-06	0.000112	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	9.14e-06	0.00011	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	9.12e-06	0.000109	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	8.94e-06	0.000107	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—APOE—multiple sclerosis	8.71e-06	0.000104	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	7.73e-06	9.28e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—POMC—multiple sclerosis	7.48e-06	8.98e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	6.87e-06	8.24e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ALB—multiple sclerosis	6.82e-06	8.18e-05	CbGpPWpGaD
